According to THE SAGE GROUP, the 2025 U.S. Prevalence of Peripheral Artery Disease (PAD) Exceeded 22 MillionBusiness Wire • 06/18/26
Here's Why Sage Group (SGPYY) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 02/20/26
Sage Group (SGPYY) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 10/22/25
The Sage Group plc (SGGEF) Presents at Sales/Trading Statement Conference TranscriptSeeking Alpha • 07/30/25
According to THE SAGE GROUP, The Current United States Prevalence of Chronic Venous Disease (CVD) Exceeds 190 Million. The Most Severe Stage, Chronic Venous Insufficiency (CVI), Afflicts Over 50 Million.Business Wire • 07/18/25
All You Need to Know About Sage Group (SGPYY) Rating Upgrade to Strong BuyZacks Investment Research • 05/26/25